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Abstract
Summary Inhibition of sympathetic signaling to bone reduces
bone resorption in rodents. In contrast, we show that pharma-
cological reduction of the sympathetic tone increases bone
resorption in humans in vivo. This effect does not appear to
be mediated via a direct pharmacological effect on the
osteoclast.
Introduction Inhibition of sympathetic signaling to bone re-
duces bone resorption in rodents. It is uncertain whether a sim-
ilar role for the sympathetic nervous system exists in humans.
The sympathetic tone can be reduced by clonidine, which acts
via alpha-2-adrenergic receptors in the brainstem. Our objec-
tive was to determine the effect of clonidine on bone turnover
in humans.
Methods The acute effect of a single oral dose of 0.3 mg clo-
nidine on serum bone turnover markers (C-terminal cross-
linking telopeptides of collagen type I (CTx), a marker for
bone resorption, and procollagen type 1 N propeptide
(P1NP), a marker for bone formation) was determined in a
randomized crossover design in 12 healthy volunteers, aged
18–70 years. In addition, we assessed the effect of clonidine
on the number of tartrate-resistant acid phosphatase–positive
multinucleated cells (TRAcP+ MNCs) and bone resorption.
Results CTx concentrations increased after clonidine treat-
ment compared to the control condition (p=0.035). P1NP
concentrations were not affected by clonidine (p=0.520).
In vitro, clonidine had no effect on the number of TRAcP+
MNCs (p=0.513) or on bone resorption (p=0.996).
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Conclusions We demonstrated that clonidine increases bone
resorption in humans in vivo. This effect does not appear to be
mediated via a direct effect on the osteoclast.
Keywords Alpha-2-adrenergic receptor . Bone turnover .
Osteoclast . Sympathetic nervous system
Introduction
Bone remodeling is under control of the sympathetic nervous
system [1–3]. Knockout of the beta-2-adrenergic receptor
(β2-AR) in osteoblasts resulted in a high bone mass pheno-
type [4]. In line, administration of a β-blocker or β-agonist
was shown to increase and decrease bone mass in mice, re-
spectively [5–7]. The role of the sympathetic nervous system
in bone turnover was further supported by the high bone mass
phenotype in mice with low sympathetic activity, due to do-
pamineβ-hydroxylase deficiency [8]. Recently, the role of the
sympathetic nervous system in bone metabolism was
extended by investigating mice with a double knockout
of alpha-2A- and alpha-2C-adrenoceptor genes [9]. Alpha-2-
adrenorecoptors are expressed in the brainstem, and when
activated, sympathetic activity is reduced. Consequently,
knockout of alpha-2-adrenoceptors resulted in chronic sympa-
thetic hyperactivity, indicated by increased norepinephrine re-
lease. Unexpectedly, these mice presented with a phenotype of
high bone mass with increased bone formation and decreased
bone resorption.
It is uncertain whether human bone metabolism is also
under control of the sympathetic nervous system.
Epidemiological studies on the association between beta-
blocker use and fracture risk showed inconclusive results,
with β-blockers having positive, negative, or no effects on
bonemass [10–22]. Two recent meta-analyses indicate a small
but significant risk reduction (15 and 17 %, respectively) of
any fracture in patients treated with beta-blockers [23, 24].
This risk reduction was, however, associated with the use of
beta-1-selective blockers, rather than non-selective beta-
blockers. A case–control study comparing bone turnover in
pheochromocytoma patients and controls showed that pheo-
chromocytoma patients have increased bone resorption,
which normalizes after adrenalectomy [25, 26]. These find-
ings support the concept of regulation of bone remodeling by
the sympathetic nervous system in humans.
Pharmacological activation of alpha-2-adrenergic receptors
in the brainstem by clonidine leads to a reduction in sympa-
thetic tone. Clonidine is typically prescribed to treat hyperten-
sion and menopausal flushes. To study the effect of the sym-
pathetic nervous system on bone in humans, we conducted a
crossover study determining the acute effect of a single oral
dose of 0.3 mg clonidine (a selective alpha-2-adrenergic re-
ceptor agonist) on bone turnover markers in 12 healthy
subjects. We hypothesized that pharmacological alpha-2-
adrenergic stimulation decreases C-terminal cross-linking
telopeptides of collagen type I (CTx) and procollagen type
1 N propeptide (P1NP) concentrations, indicating decreased
bone turnover. Unexpectedly, CTx concentrations increased
after clonidine treatment compared to the control condition,
indicating enhanced bone resorption. In view of these results,
we further investigated whether the effects of clonidine are
mediated via direct stimulation of alpha-2-adrenergic recep-
tors on the osteoclast by determining the effect of clonidine on
osteoclastogenesis and bone resorption in vitro.
Subjects and Methods
In vivo effect of clonidine on bone formation
and resorption
Subjects
Twelve healthy female and male volunteers aged 18–70 years
were recruited for this crossover study. Exclusion criteria for
participation were (1) contra-indications to clonidine, i.e., hy-
persensitivity, pulse rate <50 per minute, and use of antihy-
pertensive drugs or drugs with negative chronotropic effects
on the heart; (2) any medication or disease influencing bone
turnover; (3) blood pressure <110/70 mmHg; and (4) pregnan-
cy. At baseline, we took a complete history and measured
body weight, height, and blood pressure. A venous blood
sample was drawn after an overnight fast to determine serum
concentrations of calcium, albumin, phosphate, parathyroid
hormone (PTH), 25-hydroxyvitamin D (25(OH)D), creati-
nine, and alkaline phosphatase.
Study design
This open-label crossover trial was performed at the
Department of Endocrinology and Metabolism of the
Academic Medical Center of the University of Amsterdam
(AMC/UvA) in the Netherlands. All participating subjects
were studied two times (clonidine and control) and served as
their own control. The 2 study days were separated by a wash-
out period of at least 1 week. Participants were randomly
allocated to clonidine followed by no intervention or no inter-
vention followed by clonidine using a computer-generated
randomization list (nQuery Advisor version 7.0, Statistical
Solutions, Cork, Ireland). An antecubital vein of the arm
was cannulated for all blood sampling. A baseline blood sam-
ple was drawn between 8:30 and 9:00 h to determine bone
turnover markers (C-terminal cross-linking telopeptides of
collagen type I (CTx) and procollagen type 1 N propeptide
(P1NP)), normetanephrine, and creatinine concentrations in
plasma or serum, after which participants received either a
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single oral dose of clonidine (a selective alpha-2-adrenoceptor
agonist) 0.3 mg or no intervention at 9:00 h. Five blood sam-
ples were drawn during the following 6 h to determine bone
turnover markers, normetanephrine, and creatinine concentra-
tions. All blood samples were centrifuged within 30 min and
stored at −20 ° C until analysis. Participants were fasted
throughout the experiment but were allowed to drink water.
They were restricted to bed rest with minimal physical activ-
ity. During the experiment, blood pressure and heart rate were
monitored every 15 min, with a Microlife® BP 3 AC1-1 au-
tomatic device. The study was approved by the Institutional
Review Board of the Academic Medical Center (AMC) in
Amsterdam and was carried out in compliance with the
Helsinki Declaration. All subjects agreed to participate in the
study and written informed consent was obtained from all
participants. The trial was registered in the Netherlands Trial
Register (NTR3762) before start of the study.
Measurements and analytical procedures
SerumC-terminal cross-linking telopeptides of collagen type I
(CTx), a marker of bone resorption, and serum procollagen
type 1 N propeptide (P1NP), a marker of bone formation, were
measured as bone turnover markers. CTx and P1NP concen-
trations were measured using an immunoassay (Modular
Analytics E 170; Roche Diagnostics Corporation,
Indianapolis, IN; and Orion Diagnostica, Espoo, Finland, re-
spectively), as described earlier [27]. Plasma normetanephrine
was determined by automated online solid phase extraction
HPLC-tandem mass spectrometry as described by De Jong
et al. [28]. Serum creatinine concentrations were measured
on a Hitachi Modular 8000 (C602 and C702) (Roche
Diagnostics, Mannheim, Germany). Assays were performed
in duplicate and samples from a single subject were assayed
within the same analytical batch. Inter-assay coefficients of
variation were as follows: CTx 3 %, P1NP 8 %, and
normetanephrine 7.7 %.
Effect of clonidine on osteoclast formation and activity
Cell isolation and culture
CD14+ monocytes were isolated from human buffy coats
(Sanquin, Amsterdam, Netherlands) obtained from healthy
volunteers who provided written informed consent. Briefly,
human buffy coats were diluted with phosphate-buffered sa-
line (PBS) containing 1 % citrate (1:1) and then spun down
(800 g, 30 min, without brake) in Ficoll gradient solution. The
interphase containing the peripheral blood mononuclear cells
was collected and washed four times in 0.5 % bovine serum
albumin buffer (2 mM EDTA, phosphate-buffered saline) and
then passed through a cell strainer (40 mm) to ensure the
recovery of a clean mononuclear cell population. Cells were
counted using a Muse cell counter (Merck Millipore,
Darmstadt, Germany) and incubated with CD14 antibody
tagged microbeads (Miltenyi Biotec) (1×107 cells in 20 μL
microbead solution) for 15 min at 4 °C and then sorted using a
manual MACS magnetic cell sorter (Miltenyi Biotec) accord-
ing to the manufacturer’s instructions. This method is fre-
quently used to isolate osteoclast precursors [29]. The purity
of the cells was confirmed to be 86 % by flow cytometry
(Accuri C6, Becton Dickinson) using a FITC-labeled CD14
antibody and mouse IgG2a isotype antibody (both Miltenyi
Biotec) as control. Purified CD14+ cells were suspended in
culture medium consisting of αMEM (Life Technologies)
supplemented with 10 % fetal calf serum (HyClone I), 1 %
penicillin/streptomycin (Sigma-Aldrich), and 25 ng/mL mac-
rophage colony-stimulating factor (M-CSF) (R&D systems).
Bovine cortical bone slices of 650-μm thickness were soaked
in a 96-well plate with 100 μL culture medium for 2 h prior to
seeding. Next, the medium was removed and 75 μL of medi-
um containing 25 ng/mLM-CSFwas added to the bone slices,
upon which 75μL of cell suspension containing 1.5*105 cells
was added. After 3 days of culturing withM-CSF, the medium
composition was changed to 10 ng/mL M-CSF and 2 ng/mL
receptor activator of nuclear factor kappa-B ligand (RANKL)
(R&D Systems). All cultures were maintained at 37 °C, in a
humidified atmosphere under 5 % CO2. Culture media were
replaced every 3–4 days.
A time titration experiment was performed first, to deter-
mine the appropriate point in time to add clonidine. In this
experiment, CD14+ cells were cultured for 28 days, with col-
lection of samples for tartrate-resistant acid phosphatase
(TRAcP) staining and bone resorption at days 7, 10, 14, 17,
21, 24, and 28. On day 17, wells were dissolved in RNA lysis
buffer from the RNeasy Mini Kit (Qiagen, Hilden, Germany)
and stored at −80 °C for RNA isolation to determine messen-
ger RNA (mRNA) expression of osteoclast-related genes (tar-
trate-resistant acid phosphatase (TRAP), cathepsin K (CTSK),
calcitonin receptor (CALCR), and dendritic-cell-specific
transmembrane protein (DCSTAMP)) and of alpha-2-
adrenergic receptor subtypes (ADRA2A, ADRA2B,
ADRA2C). Based on the bone resorption results from this
experiment (data not shown), we decided to add clonidine
after 14 days of culturing.
In a separate experiment, clonidine (Sigma-Aldrich) was
added to the culture medium after 14 days of culturing in in-
creasing concentrations (10−9, 10−7, and 10−5 M). These con-
centrations were chosen based on peak plasma concentrations
achieved after a single oral dose of clonidine 0.3mg [30, 31] and
concentrations used in a previous in vitro study using mouse
osteoclasts [9]. Wells containing the solvent (water) used for
clonidine served as controls. After 14, 21, and 28 days of cul-
turing, wells were washed with PBS and the cells were either
fixed in 4% formaldehyde (used for TRAcP staining) or washed
with water (used for bone resorption) and stored at 4 °C.
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All cultures were run at least in fivefold (for TRAcP stain-
ing), in tenfold (for bone resorption), and in sixfold (for RNA
analysis).
TRAcP staining and cell count
Osteoclast-like cells were defined as multinucleated (three or
more nuclei) tartrate-resistant acid phosphatase (TRAcP)–
positive cells. After 14, 21, and 28 days of culturing, TRAcP
positivity was determined by enzyme histochemistry
(Leukocyte Acid Phosphatase Staining Kit, Sigma-Aldrich).
Nuclei were stained with diamidino-2-phenylindole
dihydrochloride (DAPI). Per bone slice, the number of
TRAcP-positive cells with three or more nuclei were counted
at a ×200 magnification. We considered multinucleated cells
with three to five nuclei as small osteoclasts and multinucle-
ated cells with more than five nuclei as large osteoclasts. The
data were expressed as number of TRAcP+ multinucleated
cells (MNCs) per square centimeter.
Osteoclast resorption assay
In order to evaluate osteoclast activity, resorption was ana-
lyzed after a culture period of 14, 21, and 28 days. Cells were
lysed with demineralized water, after which bone slices were
sonicated for 30 min in 10 % ammonium to remove the cell
remnants. Bone slices were then thoroughly washed with
demineralized water and subsequently incubated in a 10 %
saturated alum (KAl(SO4)2·12H2O) solution for 10 min.
Finally, the bone slices were washed again with demineralized
water and the resorption pits were stained with Coomassie
brilliant blue. An entire bone slice was micrographed at a
×200 magnification, using a digital camera, mounted on a
light microscope (both from Leica, Wetzlar, Germany). We
reconstructed the bone slices by merging the micrographs
using Adobe Creative Suite Bridge (San Jose, CA, USA).
The resorbed area was measured using Image Pro-Plus
Software (Media Cybernetics, Silver Spring, MD, USA) and
expressed as percentage of the total surface area.
RNA isolation and qPCR
Gene expression of osteoclast-related genes (TRAP, CTSK,
CALCR, and DCSTAMP) and of alpha-2-adrenergic receptor
subtypes (ADRA2A, ADRA2B, ADRA2C) was quantified
by PCR at 17 days of culturing. Total RNA was extracted
using the RNeasy Mini Kit (Qiagen) according to the manu-
facturer’s instructions. Reverse transcription of RNAwas per-
formed using the MBI Fermentas cDNA synthesis kit
(Fermentas, Lithuania), using both the Oligo(dT)18 and the
D(N)6 primers. Quantitative PCR (qPCR) was performed on
the ABI PRISM 7000 Sequence Detection System as de-
scribed previously [32]. Primers were designed using the
Primer Express software (version 2.0, Applied Biosystems,
Foster City, CA, USA) (Table 1). To avoid amplification of
genomic DNA, primers were designed such that each
amplicon spanned at least one intron. The PCR reactions of
the different amplicons had equal efficiencies as determined
by serial dilutions of a calibrator sample. For the PCR analy-
sis, porphobilinogen deaminase (PBGD) was used as house-
keeping gene. Expression of this gene was not affected by the
experimental conditions. Samples were normalized for the
expression of PBGD by calculating the ΔCt (Ctgene of interest
−CtPBGD). Expression of the different genes is expressed as
2−(ΔCt).
Statistical analysis
All data were analyzed using SPSS for Windows (version
21.0, SPSS Inc., Chicago, IL, USA). The mean and standard
deviation (SD) or the median and interquartile range (IQR) are
reported depending on the distribution. To determine the
acute effect of a single oral dose of a selective alpha-2-
adrenoceptor agonist versus no intervention on bone turnover
and normetanephrine concentrations, we performed linear
mixed model analysis with treatment and time as categorical
fixed effects with correction for repeated measurements
(AR1). The assumptions of the model were met (e.g., normal-
ly distributed residuals and homogeneous variances). For post
hoc analysis of bone turnover marker and normetanephrine
concentrations at the different time points, we used the paired
t test.
Comparisons of the number of TRAcP+ MNCs and
percentage of resorbed bone area over time and between
the different culture conditions at day 21 and day 28
were made with a Kruskal–Wallis test, followed by post





We enrolled a total of 12 eligible study participants: four men,
and five premenopausal and three postmenopausal women
with a median age of 27 (IQR 32) years. All subjects had
calcium, albumin, phosphate, PTH, and alkaline phosphatase
concentrations within the reference range and normal kidney
function. The median 25(OH)D concentration was 50 (IQR
24) nmol/L. None of the participants had a (family) history of
bone diseases or fractures. Two subjects were current moder-
ate smokers, and two were former smokers. None of the study
subjects used >2 units alcohol/day. Three premenopausal
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women used monophasic combined oral contraceptives.
All had their tablet-free interval during the control day
of the experiment. Two women had a regular menstrual
cycle and were in the follicular phase during the inter-
vention with clonidine. The other subjects did not use
any medication.
Sympathetic nervous system and bone turnover markers
Stimulation of alpha-2-adrenoceptors by clonidine leads to a
reduction in central sympathetic outflow and a resultant
decrease in blood pressure, as well as a decrease in
catecholamine release from sympathetic nerves. Plasma
normetanephrine, a norepinephrine metabolite, concen-
trations can be regarded as a marker of sympathetic
tone. As expected, blood pressure (data not shown)
and normetanephrine concentrations declined after cloni-
dine treatment (Fig. 1a). Baseline CTx (bone resorption)
and P1NP (bone formation) concentrations were not different
between the intervention and control days (p=0.398 and
p=0.196, respectively). CTx was higher after clonidine
compared to the control condition (time*intervention ef-
fect, p=0.035) (Fig. 1b). The effect was most evident
2 h (11:00) after clonidine administration, with CTx
concentrations of 568.5±150.9 versus 474.9±143.1 ng/L in
the control condition (p=0.001). CTx concentrations
remained significantly different throughout the remainder of
the experiment (13:00, p=0.005, and 15:00, p=0.028). P1NP
concentrations were not affected by clonidine (p=0.520)
(Fig. 1c).
In vitro experiment
Formation of TRAcP+ MNCs and bone resorption
Tartrate-resistant acid phosphatase–positive (TRAcP+)
multinucleated cells (MNCs) were observed after
14 days of culturing (Fig. 2a). The number of
TRAcP+ MNCs increased in the course of the experi-
ment, with a significant difference in the number of
TRAcP+ MNCs (3–5 nuclei, 5+ nuclei, and total num-
ber) between 14 and 28 days of culturing (p=0.003,
p=0.008, and p=0.003). The total number of TRAcP+
MNCs increased from 103 (IQR 32) on day 14 to 649
(IQR 233) TRACP+ MNCs/cm2 on day 28 of culturing
(Fig. 2b).
Bone resorption pits could be visualized at 14 days
of culturing (Fig. 3a). In line with the formation of
TRAcP+ MNCs, there was an increase in bone resorp-
tion from 1.1 (IQR 0.7) % to 6.9 (IQR 4.6) % of re-
sorbed bone area between day 14 and day 28 of culturing
(p=0.001) (Fig. 3b).
mRNA expression
At 17 days of culturing, osteoclast-like cells generated from
human CD14+ cells expressed mRNA for all investigated
osteoclast-related genes, TRAP, CTSK, CALCR, and
DCSTAMP (Ct values of 17.5–29.3 cycles), as well as the
three alpha-2-adrenergic receptor subtypes (Ct values of
26.0–30.1 cycles).
Table 1 qPCR primer sequences



























For each gene, the first oligonucleotide sequence represents the forward primer and the second sequence, the
reverse primer
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Effect of clonidine on osteoclast formation and osteoclast
activity
No significant effect of clonidine on the number of TRAcP+
MNCs (3–5 nuclei, 5+ nuclei, and total number) could be
observed after 21 (p=0.446, p=0.380, and p=0.693) and
28 days (p=0.864, p=0.454, and p=0.513) of culturing
(Fig. 2b).
The percentage of resorbed bone area did not also signifi-
cantly differ between clonidine and control at 21 and 28 days
of culturing (p=0.789 and 0.996, respectively) (Fig. 3b).
Discussion
In this study, we demonstrated that a pharmacological
decrease of the sympathetic nervous system tonus by clo-
nidine, an alpha-2-adrenergic receptor agonist, increases
CTx concentrations in humans in vivo, indicating en-
hanced bone resorption. We demonstrated expression of
alpha-2-adrenoceptors by human osteoclast-like cells, but
in vitro osteoclast formation and activity were not affected
by clonidine.
Our data indicate that pharmacological inhibition of the





























































Fig. 1 Normetanephrine (nmol/L) (a); C-terminal cross-linking
telopeptides of collagen type I (CTx) (ng/L), a marker for bone resorption
(b); and procollagen type 1 N propeptide (P1NP) (μg/L), a marker for
bone formation (c) on the control (open dots) and intervention (closed
dots) time points. Normetanephrine concentrations declined after cloni-
dine treatment (time*intervention effect, p<0.001). CTx was higher after
clonidine compared to control (time*intervention effect, p=0.035). P1NP
concentrations were not affected by clonidine (time*intervention effect,




























































Fig. 2 Representative example of tartrate-resistant acid phosphatase–
positive (TRAcP+) multinucleated cell (MNC) (three nuclei or more)
(arrows) formed from CD14+ monocytes isolated from human buffy coat
at day 21. Scale bar=50 μm (a). Formation of TRAcP+ MNCs at culture
days 14, 21, and 28. Data are expressed as total number of TRAcP+
MNCs per square centimeter (mean±SEM). **p<0.01. CLO=clonidine
(b)
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is compatible with recent findings in alpha-2A/C-adrenergic
receptor knockout mice, in which increased sympathetic ac-
tivity was associated with decreased bone resorption and high
bone mass [9]. Both results oppose the general view that the
sympathetic nervous system has a catabolic effect on the skel-
eton [4, 6, 5, 7, 8] and suggest that the observed changes in
bone resorption are not sympathetically driven but mediated
via direct stimulation of the alpha-2-adrenergic receptors on
bone cells. To confirm this hypothesis, we investigated the
effect of clonidine on osteoclasts that were cultured in vitro.
Osteoclast-like cells did express mRNA for all alpha-2-
adrenergic subtypes, but osteoclast formation and activity
were not affected by clonidine. These results are in line with
previous observations. Arai et al. showed that treatment with
clonidine does not affect the resorbing activity of human
osteoclast-like cells generated from bone marrow obtained
during artificial hip replacement surgery [33]. In contrast,
Fonseca et al. showed that osteoclasts generated from
mouse bone marrow increased in number (51 %) and activ-
ity (2.6-fold) in response to clonidine. The clonidine concen-
trations used were comparable to the concentrations in our
experiment [9]. A major difference between this study and
ours is that we generated osteoclast-like cells from CD14+
cells selected from human buffy coats, while Fonseca et al.
used osteoclasts that were cultured from mouse long bone
marrow. Taken together, these data strongly suggest that oste-
oclasts generated from CD14+ osteoclasts precursors of hu-
man origin do not respond to clonidine whereas those of
mouse origin do.
An explanation for the conflicting results from our in vivo
and in vitro experiments remains speculative. The clonidine
concentrations in the in vitro experiment were based on
in vivo peak plasma concentrations achieved after a single oral
dose of 0.3 mg clonidine [30, 31] and on concentrations from
a previous osteoclast culture experiment in rodents [9] and
should therefore be sufficient.
The osteoclast-like cells we generated fulfilled the func-
tional criteria of mature osteoclasts, with positive TRAcP
staining, formation of resorption pits on bone slices, and ex-
pression of osteoclast-related genes. It is, however, not certain
that these osteoclast-like cells behave similar to osteoclasts
in vivo. In vitro generated osteoclasts are formed by adding
cytokines (M-CSF and RANKL) to the culture medium,
whereas in vivo the interaction between precursors and cells
of the osteoblastic lineage appears to be essential. Therefore,
in volunteers, coupling between osteoclasts and other bone
cells may have taken place, which is absent in our CD14+ cell
cultures. It is therefore likely that clonidine increases bone
resorption indirectly, via osteocytes and/or osteoblasts.
Indeed, these cells have been reported to express the alpha-
2-adrenergic receptor [33–36] and osteocytes have recently
been recognized as a major player in skeletal activity [37].
This would explain the observed discrepancy between the
in vivo and in vitro effects of clonidine.
In vivo CTx concentrations increased after clonidine ad-
ministration, indicating increased bone resorption. Clonidine
also lowered arterial blood pressure, but not to such an extent
that renal perfusion was compromised causing modified CTx
clearance. Since plasma creatinine concentrations were not
different between the two experimental conditions (data not
shown), it is unlikely that the increase in CTx after clonidine is
caused by reduced renal clearance of CTx. Other causes for
the increase in CTx concentrations also need to be considered.
A single oral dose of clonidine increases plasma growth hor-
mone levels [38]. However, in a recent study in obese premen-
opausal women, growth hormone administration for 6 months
did not significantly increase CTx levels [39]. Alpha-2-
adrenergic receptor agonists have been reported to increase
blood glucose levels [40], which might also influence bone
turnover. We did not find a significant difference in glucose




























































Fig. 3 Representative example of resorption pits (RP) (arrows) stained
with Coomassie brilliant blue at day 21. Scale bar=100 μm (a). Bone
resorption at culture days 14, 21, and 28. Data are expressed as resorbed
area as percentage of total surface area (mean±SEM). ***p<0.001.
CLO=clonidine (b)
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making this explanation for the increase in CTx levels unlike-
ly. Although we included in the in vivo experiment a hetero-
geneous group of only 12 subjects, we could demonstrate a
robust effect of clonidine on bone resorption. This strengthens
the biological relevance of the effect across different ages and
sex. In addition, since baseline bone turnover marker concen-
trations were not significantly different between the interven-
tion and control day, it is unlikely that other factors account for
the changes in CTx concentrations we observed.
The clinical relevance of the increased bone resorption ob-
served with clonidine needs to be considered. Clonidine is
licensed for the treatment of hypertension, migraine, and post-
menopausal vasomotor symptoms. Of note, postmenopausal
women are already challenged with an increase in bone turn-
over. We did not investigate the long-term effect of clonidine
use on bone turnover. However, based on the acute effect of a
single oral dose of clonidine, prolonged treatment with cloni-
dine could potentially aggravate the risk of developing osteo-
porosis. There are currently no studies on the association be-
tween long-term use of clonidine and bone mineral density or
risk fracture.
In conclusion, an acute decrease in the sympathetic tone by
clonidine increases bone resorption in humans in vivo. This
effect does not appear to be mediated via direct stimulation of
alpha-2-adrenergic receptors on the osteoclast.
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